{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:48:27Z","timestamp":1795045707309,"version":"4.10.2"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014091","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021515","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021515","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Nirsevimab is an extended half-life, highly potent, anti-respiratory syncytial virus (RSV) fusion protein neutralizing monoclonal antibody with efficacy against RSV-associated medically attended (MA) lower respiratory tract infection (LRTI) in infants and medically vulnerable children (aged \u226424 months). This post hoc exploratory analysis examined the incidence of LRTI from RSV and other respiratory pathogens during MELODY: a 2:1 randomized, double-blind, placebo-controlled, phase 3 study of nirsevimab in healthy term and late preterm (ie, gestational age \u226535 weeks) infants entering their first RSV season.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 3012 participants were randomized to nirsevimab (n = 2009) or placebo (n = 1003). Nasopharyngeal swabs were collected from infants who presented with an LRTI and tested for 22 different respiratory pathogens using the BioFire\u00ae Respiratory 2.1 Panel. Incidence of RSV and non-RSV MA-LRTIs through day 511 and LRTI severity were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 852 nasopharyngeal swabs were collected from 561 participants through day 511: 519 swabs from 337 nirsevimab participants and 333 swabs from 224 placebo participants. RSV and non-RSV infections were detected in 193 of 852 (22.7%) and 55 of 852 (64.7%) swabs, respectively. RSV infection rates were lower with nirsevimab compared with placebo, including RSV\u2013rhinovirus\/enterovirus coinfections. Rates of other viral infections were similar between study arms. Approximately 70% of single RSV infections and RSV coinfections were adjudicated as mild, and 26.2% of single RSV infections and 24.5% of RSV coinfections required hospitalization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Nirsevimab protected against RSV single and coinfections, with no evidence of replacement of RSV with other respiratory viruses.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT03979313.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae596","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:11:01Z","timestamp":1733839861000},"page":"634-644","source":"Crossref","is-referenced-by-count":31,"title":["Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-9706","authenticated-orcid":false,"given":"Doug","family":"Arbetter","sequence":"first","affiliation":[{"name":"Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-035X","authenticated-orcid":false,"given":"Vancheswaran","family":"Gopalakrishnan","sequence":"additional","affiliation":[{"name":"Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia A","family":"Aksyuk","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Ahani","sequence":"additional","affiliation":[{"name":"Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chang","sequence":"additional","affiliation":[{"name":"Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-1046","authenticated-orcid":false,"given":"Ron","family":"Dagan","sequence":"additional","affiliation":[{"name":"Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev , Beer-Sheva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T","family":"Esser","sequence":"additional","affiliation":[{"name":"Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L","family":"Hammitt","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali S","family":"Mankad","sequence":"additional","affiliation":[{"name":"Clinical Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1149-5905","authenticated-orcid":false,"given":"Xavier","family":"Saez-Llorens","sequence":"additional","affiliation":[{"name":"Cevaxin Research Center , Panama City ,","place":["Panama"]},{"name":"Department of Infectious Diseases, Hospital del Ni\u00f1o Dr Jos\u00e9 Ren\u00e1n Esquivel , Panama City ,","place":["Panama"]},{"name":"SNI, National Secretariat of Science, Technology and Innovation , Panama City ,","place":["Panama"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shen","sequence":"additional","affiliation":[{"name":"Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Leach","sequence":"additional","affiliation":[{"name":"Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6988-8576","authenticated-orcid":false,"given":"Elizabeth J","family":"Kelly","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Villafana","sequence":"additional","affiliation":[{"name":"Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"2025100602574590400_ciae596-B1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1473-3099(17)30396-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015","volume":"17","author":"GBD 2015 LRI Collaborators","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025100602574590400_ciae596-B2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"2025100602574590400_ciae596-B3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ppul.23570","article-title":"Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis","volume":"52","author":"Stein","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2025100602574590400_ciae596-B4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/QCO.0000000000000952","article-title":"The disease burden of respiratory syncytial virus in infants","volume":"36","author":"Munro","year":"2023","journal-title":"Curr Opin Infect Dis"},{"key":"2025100602574590400_ciae596-B5","author":"US Food and Drug Administration"},{"key":"2025100602574590400_ciae596-B6","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025100602574590400_ciae596-B7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100602574590400_ciae596-B8","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants","volume":"388","author":"Muller","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100602574590400_ciae596-B9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100602574590400_ciae596-B10","author":"Sanofi press release","year":"2023"},{"key":"2025100602574590400_ciae596-B11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cid\/ciw756","article-title":"Severity of respiratory syncytial virus lower respiratory tract infection with viral coinfection in HIV-uninfected children","volume":"64","author":"Mazur","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025100602574590400_ciae596-B12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100602574590400_ciae596-B13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025100602574590400_ciae596-B14","doi-asserted-by":"crossref","first-page":"e2355033","DOI":"10.1001\/jamanetworkopen.2023.55033","article-title":"Contribution of infant rhinovirus bronchiolitis to hospital bed and ventilation use","volume":"7","author":"Horvat","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025100602574590400_ciae596-B15"},{"key":"2025100602574590400_ciae596-B16","first-page":"010408","article-title":"Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis","volume":"5","author":"Shi","year":"2015","journal-title":"J Glob Health"},{"key":"2025100602574590400_ciae596-B17","doi-asserted-by":"crossref","first-page":"e0157665","DOI":"10.1371\/journal.pone.0157665","article-title":"Development and validation of a new clinical scale for infants with acute respiratory infection: the ReSViNET scale","volume":"11","author":"Justicia-Grande","year":"2016","journal-title":"PLoS One"},{"key":"2025100602574590400_ciae596-B18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"2025100602574590400_ciae596-B19","doi-asserted-by":"crossref","first-page":"15455","DOI":"10.3390\/ijerph192315455","article-title":"Respiratory syncytial virus pediatric hospitalization in the COVID-19 era","volume":"19","author":"Bozzola","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025100602574590400_ciae596-B20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"2025100602574590400_ciae596-B21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jpids\/piad113","article-title":"Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season","volume":"13","author":"Dagan","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025100602574590400_ciae596-B22","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41591-023-02316-5","article-title":"Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants","volume":"29","author":"Wilkins","year":"2023","journal-title":"Nat Med"},{"key":"2025100602574590400_ciae596-B23","doi-asserted-by":"crossref","first-page":"104493","DOI":"10.1016\/j.ebiom.2023.104493","article-title":"The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study","volume":"90","author":"Dagan","year":"2023","journal-title":"EBioMedicine"},{"key":"2025100602574590400_ciae596-B24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(19)30721-4","article-title":"Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study","volume":"394","author":"Pneumonia Etiology Research for Child Health (PERCH) Study Group","year":"2019","journal-title":"Lancet"},{"key":"2025100602574590400_ciae596-B25","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/v13071249","article-title":"Epidemiology of the rhinovirus (RV) in African and Southeast Asian children: a case-control pneumonia etiology study","volume":"13","author":"Baillie","year":"2021","journal-title":"Viruses"},{"key":"2025100602574590400_ciae596-B26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/INF.0000000000003865","article-title":"A hypothesis-generating prospective longitudinal study to assess the relative contribution of common respiratory viruses to severe lower respiratory infections in young children","volume":"42","author":"Ben-Shimol","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"2025100602574590400_ciae596-B27","doi-asserted-by":"crossref","first-page":"101337","DOI":"10.1016\/j.coviro.2023.101337","article-title":"Structural basis for respiratory syncytial virus and human metapneumovirus neutralization","volume":"61","author":"Miller","year":"2023","journal-title":"Curr Opin Virol"},{"key":"2025100602574590400_ciae596-B28","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(22)01277-6","article-title":"Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption","volume":"400","author":"Messacar","year":"2022","journal-title":"Lancet"},{"key":"2025100602574590400_ciae596-B29","first-page":"195","article-title":"The effects of the COVID-19 pandemic on community respiratory virus activity","volume":"21","author":"Chow","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2025100602574590400_ciae596-B30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.15585\/mmwr.mm7140a1","article-title":"Respiratory virus surveillance among children with acute respiratory illnesses\u2014New Vaccine Surveillance Network, United States, 2016\u20132021","volume":"71","author":"Perez","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025100602574590400_ciae596-B31","doi-asserted-by":"crossref","first-page":"e2336863","DOI":"10.1001\/jamanetworkopen.2023.36863","article-title":"Pediatric RSV-associated hospitalizations before and during the COVID-19 pandemic","volume":"6","author":"Bourdeau","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025100602574590400_ciae596-B32","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/v15091825","article-title":"Comparative analysis of pediatric hospitalizations during two consecutive influenza and respiratory virus seasons post-pandemic","volume":"15","author":"Presti","year":"2023","journal-title":"Viruses"},{"key":"2025100602574590400_ciae596-B33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3201\/eid2802.211727","article-title":"Viral interference between respiratory viruses","volume":"28","author":"Piret","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2025100602574590400_ciae596-B34","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/resp.12741","article-title":"Systematic review and meta-analysis of respiratory viral coinfections in children","volume":"21","author":"Lim","year":"2016","journal-title":"Respirology"},{"key":"2025100602574590400_ciae596-B35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcv.2016.04.019","article-title":"Respiratory viral coinfection and disease severity in children: a systematic review and meta-analysis","volume":"80","author":"Scotta","year":"2016","journal-title":"J Clin Virol"},{"key":"2025100602574590400_ciae596-B36","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1038\/s41467-024-46648-3","article-title":"Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"2025100602574590400_ciae596-B37","doi-asserted-by":"crossref","first-page":"2400033","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033","article-title":"Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023\/24 season in Luxembourg","volume":"29","author":"Ernst","year":"2024","journal-title":"Euro Surveill"},{"key":"2025100602574590400_ciae596-B38","doi-asserted-by":"crossref","first-page":"2400046","DOI":"10.2807\/1560-7917.ES.2024.29.6.2400046","article-title":"Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024","volume":"29","author":"L\u00f3pez-Lacort","year":"2024","journal-title":"Euro Surveill"},{"key":"2025100602574590400_ciae596-B39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/B978-0-12-375156-0.00010-2","volume-title":"Fenner and White's medical virology","author":"Burrell","year":"2017","edition":"5th ed."},{"key":"2025100602574590400_ciae596-B40","doi-asserted-by":"crossref","first-page":"104538","DOI":"10.1016\/j.jcv.2020.104538","article-title":"Clinical evaluation of the BioFire\u00ae Respiratory Panel 2.1 and detection of SARS-CoV-2","volume":"129","author":"Creager","year":"2020","journal-title":"J Clin Virol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae596\/60950219\/ciae596.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/3\/634\/60950219\/ciae596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/3\/634\/60950219\/ciae596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:57:57Z","timestamp":1759733877000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/3\/634\/7916422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2025,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae596","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2024,12,4]]}}}